TABLE 1.

Clinical information of pancreatic cancer patients in the training, validation, and entire cohort.

Variable	Entire cohort (n = 177)	Training cohort (n = 107)	Validation cohort (n = 70)	p-value
Age
≤ 65	93(52.54%)	53(49.53%)	40(57.14%)	0.4023
> 65	84(47.46%)	54(50.47%)	30(42.86%)
Gender
Female	80(45.2%)	52(48.6%)	28(40%)	0.3324
Male	97(54.8%)	55(51.4%)	42(60%)
Grade
G1–2	125(70.62%)	76(71.03%)	49(70%)	0.4866
G3–4	50(28.25%)	29(27.1%)	21(30%)
GX	2(1.13%)	2(1.87%)	0(0%)
Stage
I–II	167(94.35%)	102(95.33%)	65(92.86%)	1
III–IV	7(3.95%)	4(3.74%)	3(4.29%)
Unknown	3(1.69%)	1(0.93%)	2(2.86%)
T stage
T1–2	31(17.51%)	22(20.56%)	9(12.86%)	0.3011
T3–4	144(81.36%)	85(79.44%)	59(84.29%)
Unknown	2(1.13%)	0(0%)	2(2.86%)
M stage
M0	79(44.63%)	48(44.86%)	31(44.29%)	0.9106
M1	4(2.26%)	2(1.87%)	2(2.86%)
MX	94(53.11%)	57(53.27%)	37(52.86%)
N stage
N0	49(27.68%)	33(30.84%)	16(22.86%)	0.1963
N1	123(69.49%)	72(67.29%)	51(72.86%)
NX	5(2.82%)	2(1.87%)	3(4.29%)